Gut Microbiome Manipulation Reverses Autoimmune Disease
Precision probiotics lead to remission in 67% of rheumatoid arthritis patients in landmark trial.
1The Microbiome Connection
A groundbreaking clinical trial has demonstrated that precision-engineered probiotics can induce remission in 67% of patients with moderate-to-severe rheumatoid arthritis, establishing a direct causal link between gut microbiome composition and autoimmune disease activity .
2Precision Probiotics
The therapy, developed by researchers at the Weizmann Institute, uses machine learning to analyze each patient's unique microbiome profile and design a personalized consortium of 12-15 bacterial strains . These strains were selected for their ability to modulate specific immune pathways implicated in joint inflammation.
3Clinical Remission Data
After 16 weeks of daily oral supplementation, treated patients showed a mean reduction of 4.2 points on the DAS28 disease activity score compared to 0.8 points in the placebo group . Remarkably, 34% of responders maintained remission for 6 months after discontinuing the probiotic.
4Future of Gut Medicine
The study also revealed that responders shared a common pattern of increased Faecalibacterium prausnitzii and decreased Prevotella copri — providing a potential biomarker for predicting treatment success . This personalized approach represents a paradigm shift from one-size-fits-all probiotics.
- 67% remission rate in moderate-to-severe rheumatoid arthritis
- Personalized probiotic consortia of 12-15 strains per patient
- 4.2-point DAS28 reduction vs 0.8 in placebo
- 34% maintained remission 6 months after stopping treatment
- Microbiome biomarkers predict treatment response
Dive Deeper into the Research
Switch to PhD Mode to explore the underlying papers, knowledge graph connections, pathway analyses, and collaborate with researchers working on Rheumatoid Arthritis.
In This Article
Related Conditions
Active Clinical Trials
Phase III: Microbiome Study
Recruiting at 12 sites nationwide
Related Articles
Researcher Interest
4,102 consumers have expressed interest in this topic. Researchers studying Rheumatoid Arthritis can see anonymized demand signals.
Gut Microbiome Manipulation Reverses Autoimmune Disease
Precision probiotics lead to remission in 67% of rheumatoid arthritis patients in landmark trial.
1The Microbiome Connection
A groundbreaking clinical trial has demonstrated that precision-engineered probiotics can induce remission in 67% of patients with moderate-to-severe rheumatoid arthritis, establishing a direct causal link between gut microbiome composition and autoimmune disease activity .
2Precision Probiotics
The therapy, developed by researchers at the Weizmann Institute, uses machine learning to analyze each patient's unique microbiome profile and design a personalized consortium of 12-15 bacterial strains . These strains were selected for their ability to modulate specific immune pathways implicated in joint inflammation.
3Clinical Remission Data
After 16 weeks of daily oral supplementation, treated patients showed a mean reduction of 4.2 points on the DAS28 disease activity score compared to 0.8 points in the placebo group . Remarkably, 34% of responders maintained remission for 6 months after discontinuing the probiotic.
4Future of Gut Medicine
The study also revealed that responders shared a common pattern of increased Faecalibacterium prausnitzii and decreased Prevotella copri — providing a potential biomarker for predicting treatment success . This personalized approach represents a paradigm shift from one-size-fits-all probiotics.
- 67% remission rate in moderate-to-severe rheumatoid arthritis
- Personalized probiotic consortia of 12-15 strains per patient
- 4.2-point DAS28 reduction vs 0.8 in placebo
- 34% maintained remission 6 months after stopping treatment
- Microbiome biomarkers predict treatment response
Dive Deeper into the Research
Switch to PhD Mode to explore the underlying papers, knowledge graph connections, pathway analyses, and collaborate with researchers working on Rheumatoid Arthritis.
In This Article
Related Conditions
Active Clinical Trials
Phase III: Microbiome Study
Recruiting at 12 sites nationwide
Related Articles
Researcher Interest
4,102 consumers have expressed interest in this topic. Researchers studying Rheumatoid Arthritis can see anonymized demand signals.